New startup ideas · Health and bio · Healthcare and bio
startup idea
Benchflow
Order any preclinical assay from inside your ELN; labs sell spare instrument time.
Benchflow is a marketplace for preclinical research services and instrument capacity.
- Marketplace
- Enterprise
- $1-10B market
- Platform others build on
- Global from day one
3/5
venture judge
5
similar startups, last 2 years (20 all-time)
97%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$900 · 4 weeks · 25 prospects
For $900 and four weeks, learn whether seed-stage biotechs will prepay posted prices for protein characterization runs and whether labs will hold those prices through delivery.
Riskiest assumption · A seed-stage biotech scientist will prepay a posted price for a characterization run from a lab they have never vetted, and the lab will deliver at that price without turning the order back into a bespoke quote.
1Focus group: who and where
Founding scientist or protein sciences lead at a 2-15 person biotech that raised a seed round in the last 24 months, rents bench space, has a characterization run (SEC-MALS, intact mass, thermal stability) due in the next 30 days, and owns none of the instruments
where to find 25 · The public resident-company rosters of LabCentral and BioLabs sites (a directory of exactly these companies), the Bits in Bio Slack (the community where these scientists compare vendors), and Discovery on Target in Boston this fall (the discovery-stage conference this buyer already attends); for the supply side, the ABRF core facility directory lists academic cores with idle instrument hours
2Sell first, build later
A protein characterization run at a posted price with a 10-business-day guaranteed turnaround and no MSA: sign a one-page order form, ship samples, get the report on the promised date, with the rate card locked for six months for the first 10 companies
the ask · Posted per-run prices from $1,400 per SEC-MALS sample set, with a $500 deposit per order credited to the total
a real yes · A real yes is a signed order form plus the $500 deposit paid; a real supply yes is a lab's signature on fixed prices; a scientist saying CRO quoting is painful, a lab saying 'send us the details and we will quote', or a request for a demo is not a yes
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Posted-price order ask
$150 · 14 days
Build a one-page rate card: three assays (SEC-MALS, intact mass, thermal stability) at fixed prices set 20% above published academic core rates, with a 10-business-day guaranteed turnaround and no master service agreement. Email and DM 25 buyers from the LabCentral and BioLabs rosters and Bits in Bio, and ask each with a live need to sign a one-page order form and pay a $500 deposit on their next run.
keep going if · 5 of 25 sign an order form and pay the $500 deposit
2. Core posted-price agreements
$100 · 14 days
Call 15 academic cores from the ABRF directory and 5 independent contract labs, and ask each to sign a one-page agreement holding a fixed external price and 10-business-day turnaround on the three assays for 90 days. This attacks the bespoke-quoting risk directly: count who will put a number in writing.
keep going if · 8 of 20 labs sign fixed price and turnaround for 90 days
3. Run five orders at posted price
$650 · 15 days
Route the first prepaid orders to signing labs, with the founder handling sample logistics and overnight cold-chain shipping. Measure whether the posted price survives contact with a real sample: no requoting, turnaround met, balance paid without dispute.
keep going if · 4 of 5 runs delivered at the posted price and inside 10 business days, with the balance paid
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$500
per prospect, refundable
how · A prepaid order: the buyer signs a one-page order form at the posted price and pays a $500 deposit by ACH or card against a reservation invoice - a normal purchasing motion for a biotech buying a $1,500-4,000 run, and small enough to clear without a procurement review set up: Stripe Invoicing ↗
what it reserves · A guaranteed 10-business-day turnaround slot at the posted price, credited in full against the run's total
refund · Refundable any time before samples ship, and refunded automatically if the promised delivery date is missed
target · 5 paid deposits from 25 prospects within 3 weeks
Go: build it if
5 or more $500 deposits paid, 8 of 20 labs signed to fixed prices, and 4 of 5 completed runs delivered at the posted price and turnaround
Kill: stop if
Fewer than 2 deposits from 25 asks, or fewer than 4 of 20 labs will hold a posted price in writing, or a majority of completed runs get requoted mid-job - any of these means the marketplace is a lead-gen form
5 Scripts to run itoutreach message, landing copy, deposit terms · click to open
outreach message
You are a few months post-seed with constructs to characterize and no SEC-MALS down the hall, so every run means two weeks of chasing CRO quotes and an MSA you do not have time to negotiate. We have lined up characterization labs at posted prices - SEC-MALS, intact mass and thermal stability at fixed rates with a 10-business-day guaranteed turnaround, no MSA. The first 10 companies get the rate card locked for six months. Got 20 minutes this week to walk through your next run?
landing page
Protein characterization at a posted price, back in 10 business days SEC-MALS from $1,400 per sample set; a $500 deposit books your slot Reserve your run - refunded in full if we miss the date
deposit terms
Your $500 deposit reserves a guaranteed 10-business-day turnaround slot at the posted price and is credited against the run's total. It is refundable any time before your samples ship, and refunded automatically if we miss the promised delivery date. The remaining balance is invoiced when your results are delivered.
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
80
Idea Score, 0-100 · raw 50.0 x 1.61
Warm
competition: more crowded than 41% of ideas · headwind x0.80
+3.3
government priorities, secondary (26 matching grants)
Trend
66
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)70
- Rounds announced 2025+ in the sector69
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
68
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain75
100x potential
45
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge50
- Market size axis33
- Moat axis100
- Neighbours still alive12
- Technologist judge25
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were order, preclinical, assay, eln, labs, sell, marketplace, research.
The idea in full
- What
- Benchflow is a marketplace for preclinical research services and instrument capacity. Biotech and pharma R&D teams order protein characterization, formulation, ADME or imaging runs at posted price and turnaround; contract labs, academic core facilities and CROs list the hours their instruments sit idle. Ordering happens through embedded integrations inside electronic lab notebooks, LIMS and procurement systems rather than on a separate site, and Benchflow takes a percentage of each order plus a fee for guaranteed turnaround.
- Why now
- The radar shows a wave of companies industrializing exactly these preclinical steps: 10x Science (yc W26) on next-generation protein characterization, AbInitio Bio (yc X26) as the intelligence layer for drug manufacturing, Harbor (yc X26) as an AI-native CRO, and Scala Biodesign raised $16M Series A on 2026-03-31 for its biodesign platform. With 130 new companies tracked in this cluster in the last two years, the buyer side is a long tail of small teams that cannot negotiate CRO master agreements one by one.
- Wedge: first customer and entry point
- Protein characterization runs for seed-stage biotechs: twenty listed labs, one assay category, priced and turnaround-guaranteed, sold through two ELN vendors' integration directories.
- Path to 100x
- Outsourced preclinical research services addressable through self-serve ordering is a $1-10B flow, and a 12% take across it plus embedded ordering in every ELN supports a $1B+ company on software margins. The moat is the order history: real delivered turnaround, failure rates and price per assay across thousands of runs is data no single lab or ELN vendor has, and it becomes the routing engine other tools call.
- Ceiling
- Large pharma keeps buying under master service agreements and only the small-biotech tail transacts, holding gross merchandise value below what a $1B outcome needs.
- Closest real companies, as the generator saw them
- Harbor is building an AI-native CRO and 10x Science operates its own platform; both are supply that Benchflow lists rather than replaces, and neither gives a buyer cross-lab price and turnaround comparison. AbInitio Bio sits on the manufacturing side, downstream of where Benchflow transacts.
- Main risk
- Labs quote every job bespoke and refuse posted pricing, so the marketplace degrades into a lead-gen form with no take rate defensibility.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
3/5
12% take on a $1-10B outsourced preclinical flow is real, but the small-biotech tail alone likely cannot carry GMV to $1B.
Bootstrapper
4/5
Seed-stage biotechs already pay CROs bespoke, and a 12% take on posted protein characterization runs bills within a year on software margins.
Operator
4/5
Seed biotechs already pay CROs for these assays and order inside their existing ELN, so spend and workflow both exist today.
Technologist
2/5
An ordering form embedded in ELN directories; the ELN vendors themselves can ship posted-price lab ordering natively before order history compounds.
Risk
2/5
Distribution is two ELN vendors' integration directories, so the marketplace lives or dies on partners who can reprice or delist it.
trends
2/5
A lab-services marketplace was equally feasible in 2013 (Science Exchange), so healthcare's $590M grant pool adds only the secondary point.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (order, preclinical, assay, eln, labs, sell, marketplace, research): 20 all-time, 5 from the last two years. Same matching as Idea Check.
Real world training envs for healthcare AI models
The world’s fastest-growing online jewelry marketplace.
robots & software for farms
The AI Workforce for Biopharma
Expert STEM reasoning data for frontier AI labs.
Platform and marketplace for RL environments and AI data
Marketplace for America's most essential assets
A direct to consumer marketplace and influencer network for brands
Super Hyperlocal Marketplace for SMEs in Indonesia
Marketplace for game boosting, carries and coaching
Sporttrade | Customer first, always.
Rapid multi-omics profiling for diagnostic labs.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1595
startup-relevant grants in Healthcare and bio
$854M
awarded in the sector, tracked
118
opportunities open now in the sector
- I-Corps: Translation Potential of an Autonomous Brain-on-a-Chip Platform for Functional Drug Discoveryawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-08-14
- Novel Ocular Aerosol Drug Delivery Device for the Treatment Optimization of Glaucoma.awardhigh relevance
NIH / NEI · SBIR phase I · $277K · posted 2026-09-30
- Rapid and Highly Multiplexed Pathogen Detection for Sepsis Patients with Compressed Sensing and Digital PCRawardhigh relevance
NIH / NCHHSTP · SBIR phase I · $296K · posted 2026-09-30
- IND-enabling development of MM012, an antibody-based non-hormonal contraceptive intravaginal ringawardhigh relevance
NIH / NICHD · SBIR phase II · $1M · posted 2026-09-25
- Advancing Site-Selective Multi-Payload HER2-Targeted Conjugates to Overcome Resistance and Boost Survival in Breast and Gastric Cancersawardhigh relevance
NIH / NCI · SBIR phase II · $1M · posted 2026-09-21
- Detection and Isolation of Circulating Myeloma Cells: Toward a Minimally-Invasive CLIA-Certified Diagnostic for Multiple Myelomaawardhigh relevance
NIH / NCI · SBIR phase II · $1M · posted 2026-09-18
- AI-Powered Optimization of RNA-Directed Therapeutics to Restore Brain Glucose in Alzheimer's Diseaseawardhigh relevance
NIH / NIA · SBIR phase I · $496K · posted 2026-09-17
NIH / NIDCR · SBIR phase II · $936K · posted 2026-09-02
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 135 → 121 → 224 → 173 → 127 new companies 2022 → 2026 · 91% aliveYC F26 live: 2 in this cluster, 2% of the batch (was 6% in S26)Since February, of 442 YC companies here: 6 acquired, 6 shut down, 45 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- Marketplace
- Path to 100x
- Platform others build on
- Market size
- $1-10B market
- Capital intensity
- Capital-light (software margins)
- Speed to revenue
- Revenue within a year
- Technical depth
- Integrations, no-code
- Go-to-market
- Partners and channels
- Moat
- Data moat
- Geography
- Global from day one
- Regulation
- Unregulated
- Vibe
- Boring business
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-22 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.